sb 203580 has been researched along with amyloid beta-peptides in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (amyloid beta-peptides) | Trials (amyloid beta-peptides) | Recent Studies (post-2010) (amyloid beta-peptides) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 3,257 | 48 | 1,626 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
He, SZ; Jian, CX; Li, CJ; Liu, XC; Liu, XF | 1 |
1 other study(ies) available for sb 203580 and amyloid beta-peptides
Article | Year |
---|---|
IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells.
Topics: Amyloid beta-Peptides; Anthracenes; Butadienes; Cell Line; Humans; Imidazoles; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Interleukin-1beta; Interleukin-33; Interleukin-6; Interleukin-8; Interleukins; JNK Mitogen-Activated Protein Kinases; Macular Degeneration; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-kappa B; Nitriles; Peptide Fragments; Pyridines; Receptors, Cell Surface; Retinal Pigment Epithelium; Sulfones; Tumor Necrosis Factor-alpha | 2012 |